Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Mr. Dong-Yeon Kim

Market Cap

235.79 Billion KRW

Sector

Healthcare

Website

https://www.ilyang.co.kr

Last Update

2/22/2024, 12:00:00 PM

Description

Ilyang Pharmaceutical Co.

Read More

Overview

Value

51

Growth

29

Health

55

Management

28

Analyst Opinion

71

Total

47

All Scores Out Of 100

Best Features

  • Has a low level of debt
  • Has a history of share buybacks
  • Has a margin-of-safety above fair value
  • Liked by analysts
  • Has strong dividend growth
  • Low preportion of income is paid as dividend

Risk Factors

  • Earnings have declined recently
  • Income is not covering expenditure and investment
  • Earnings are negative
  • Altman-Z score suggests a risk of bankruptcy
  • Does not hold enough liquid assets to cover short term liabilities
  • Disliked by Twitter users
  • Poor earnings and cashflow growth
  • Price-to-earnings ratio of 661.1 is higher than the market average (19.6x)
  • Dividend could be at risk

Market Peers

007570.KS

Key Figures

PE Ratio (TTM)

661.08

Margin Of Safety (DCF)

9424.15%

Revenue Growth (5 Year Average)

0.83%

Ratings Consensus

Buy

Share Buybacks

100.00%

Dividend Yeild (TTM)

1.53%

Valuation

Value Score

51

  • Margin-of-safety of 9424.15% is better than the market average (17.95%)
  • Estimated intrinsic-value of 1.35 Million KRW is higher than current price ( 13.12 Thousand KRW)
  • Price-to-earnings ratio of 661.1 is higher than the market average (19.6x)
  • Free-cashflow-yeild of -1.77% is worse than the market average (4.7%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 1689699.9 KRW

Current Price: 14200 KRW

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

661.08x

Free Cashflow Yeild

-1.77%

PE/Earnings Growth

N/A

Price/Book

0.56x

Growth

Growth Score

29

  • 5 Year Average Cashflow growth of 24.60% is higher than the market average (12.35%)
  • 5 Year Average Revenue growth of 0.83% is lower than the market average (10.97%)
  • Revenue growth has slowed this year
  • 5 Year Average Earnings growth of -14.76% is lower than the market average (14.48%)
  • Earnings growth has slowed this year
  • Free Cashflow growth has slowed this year

Revenue Growth

0.83%

Earnings Growth

-14.76%

Cashflow Growth

24.60%

Health

Health Score

55

  • Has a low level of debt
  • Low financial Leverage
  • Normal operation does not require debt to be sustainable
  • Cashflow is negative
  • Altman-Z score suggests a risk of bankruptcy
  • Debt repayments significantly impact cashflow

Altman Z Score

0.00

Piostroski Score

6.00

Debt/Equity

0.00x

Current Assets/Liabilities

N/Ax

Free Cashflow/Total Debt

N/Ax

Debt/Capital

N/Ax

Dividend

Secure Dividend Score

0

  • Long term dividend payout ratio of -4939.64% is considered good
  • Payout ratio (TTM) of -298.49% is lower than the average (40%)
  • Dividends have shown growth over the last 5 years
  • Dividend yeild of 1.53% is less than the market average (1.85%)
  • Very unsafe
  • Dividend growth has been slowing recently
  • Spending a higher percentage of their income on dividends than last 5 years

Dividend Yeild

1.53%

Dividend Growth

-24.64%

Payout Ratio (Earnings)

-298.49%

Payout Ratio (Cashflow)

N/A

Management

Management Score

28

  • Has repurchased shares when value is good
  • Has a history of returning value to shareholders through stock buybacks
  • Return-on-capital-employed of 2.07% is lower than the market average (10%)
  • Has returned higher dividends when earnings have fallen
  • Return-on-equity of -1.96% is lower than the market average (15%)

Average Buybacks/Dilution

100.00%

Recent Buybacks/Dilution

N/A

5 Year Price Volitility

55.79%

Return On Assets

-0.97%

Return On Capital Employed

2.07%

Return On Equity

-1.96%

Return On Free Cashflow

N/A

Return On Investments

N/A

Social Sentiment

Social Sentiment Score

0

Twitter Sentiment

N/A

Stocktwits Sentiment

N/A

Analysts

Analyst Opinion

71

  • Ratings consensus is Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Ilyang Pharmaceutical Co.,Ltd

Currency

KRW

Beta

-0.141233

Vol Avg

28128

Ceo

Mr. Dong-Yeon Kim

Cik

Cusip

Exchange

KSE

Full Time Employees

640

Industry

Drug Manufacturers—Specialty & Generic

Sector

Healthcare

Ipo Date

2000-01-04

Address

110, Hagal-ro

City

Yongin

State

Country

KR

Zip

17096

Phone

82 3 1281 7851

Analysis Last Updated

2/22/2024, 12:00:00 PM

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies